ImmunityBio (IBRX) Asset Utilization Ratio (2015 - 2026)

ImmunityBio (IBRX) has reported Asset Utilization Ratio for 12 consecutive years, with 0.25 the latest figure, recorded in Q1 2026.

• In Q1 2026, Asset Utilization Ratio rose 169.96% year-over-year to 0.25; the TTM figure through Mar 2026 stood at 0.25 (up 169.96% YoY), while the FY2025 annual figure was 0.26, up 670.53% from the prior year.
• Asset Utilization Ratio improved to 0.25 in Q1 2026 per IBRX's latest filing, from 0.22 in the prior quarter.
• Across five years, Asset Utilization Ratio topped out at 0.25 in Q1 2026 and bottomed at 0.0 in Q1 2024.
• Historically, Asset Utilization Ratio has averaged 0.06 across 5 years, with a median of 0.0 in 2022.
• Annual changes were most pronounced in 2022 — Asset Utilization Ratio tumbled 75.45% — and 2025, when it surged 13527.09%.
• ImmunityBio's Asset Utilization Ratio stood at 0.0 in 2022, then soared by 97.87% to 0.0 in 2023, then surged by 2871.13% to 0.04 in 2024, then surged by 462.57% to 0.22 in 2025, then climbed by 10.61% to 0.25 in 2026.
• Business Quant data shows IBRX's Asset Utilization Ratio at 0.25 in Q1 2026, 0.22 in Q4 2025, and 0.18 in Q3 2025.